Royal Bank of Canada
ARGS

Royal Bank of Canada’s Argos Therapeutics, Inc. ARGS Stock Holding History

Royal Bank of Canada’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500
Closed -$4K – 7390
2017
Q2 		$4K Sell
500
-540
-52% -$4.6K ﹤0.01% 6161
2017
Q1 		$9K Buy
+1,040
New +$65.8K ﹤0.01% 6045

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Royal Bank of Canada's ARGS Position: Q2 2018 in Review

Royal Bank of Canada sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 66 shares.

Royal Bank of Canada first reported a position in ARGS in Q1 2014 and held it in 17 quarters. The position peaked at $11K in Q1 2017. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

  • Royal Bank of Canada reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Royal Bank of Canada sold 66 Argos Therapeutics, Inc. shares in Q2 2018.
  • Royal Bank of Canada first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 17 quarters.
  • Royal Bank of Canada's Argos Therapeutics, Inc. position peaked at $11K in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on Royal Bank of Canada's 13F filing for Q2 2018, filed 14 Aug 2018.